Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of nivobotulinumtoxinA for glabellar and lateral canthal lines
2014-005303-24Phase 3Completed
- Sponsor
- Medytox Inc.
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nivobotulinumtoxinA in glabellar furrowing, lateral canthal rhytides and Not applicable, sponsored by Medytox Inc. Primary endpoints: Incidence of adverse events, Change from baseline in vital signs and 1 more. Started Apr 2020; status: completed.
02
Drugs
nivobotulinumtoxinA
03
Conditions
glabellar furrowinglateral canthal rhytidesNot applicable
Beyond the preview
Go deeper on 2014-005303-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005303-24.